Zentalis Highlights New Azenosertib Data in Breast Cancer

Zentalis Pharmaceuticals ( (ZNTL) ) has provided an update.

On April 17, 2026, at the American Association for Cancer Research Annual Meeting in San Diego, Zentalis Pharmaceuticals reported new preclinical data for its WEE1 inhibitor azenosertib in triple-negative breast cancer. The studies showed that azenosertib, alone and in combinations with antibody-drug conjugates and chemotherapy, induced deep tumor responses and restored drug sensitivity in models resistant to established and emerging ADC therapies, pointing to potential use beyond ovarian cancer.

In parallel, the company shared real-world analyses from two independent cohorts showing that Cyclin E1-positive ovarian cancer patients, regardless of CCNE1 gene amplification, experienced shorter time to next treatment and poorer outcomes with standard care. These findings underscore a high unmet need in this large patient subset and provide clinical context for Zentalis’s late-stage azenosertib programs, which target Cyclin E1-positive platinum-resistant ovarian cancer and aim to establish the drug as a pivotal, biomarker-driven therapy in gynecologic oncology.

The most recent analyst rating on (ZNTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.

Spark’s Take on ZNTL Stock

According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses, inconsistent revenue, and sustained cash burn) despite manageable leverage. Strong technical uptrend and a positive clinical development event provide support, while valuation remains constrained by negative earnings and no dividend.

To see Spark’s full report on ZNTL stock, click here.

More about Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing targeted treatments for ovarian cancer and multiple tumor types. The company is advancing late-stage studies of azenosertib, an investigational, orally available, first-in-class WEE1 inhibitor, as both monotherapy and in combination regimens, with a biomarker-driven strategy centered on Cyclin E1-positive tumors and a goal of providing non-chemotherapy options.

Azenosertib is being developed primarily for Cyclin E1-positive platinum-resistant ovarian cancer, a biomarker-defined population that represents roughly half of PROC cases and currently lacks approved targeted therapies. The drug has received Fast Track designation from the U.S. FDA for this indication, and Zentalis is validating a Cyclin E1 companion diagnostic in its DENALI and ASPENOVA clinical trials to better identify patients most likely to benefit.

Average Trading Volume: 1,815,359

Technical Sentiment Signal: Buy

Current Market Cap: $380.2M

Find detailed analytics on ZNTL stock on TipRanks’ Stock Analysis page.